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MMSA – What is it?
• SSRIs or anti-libidinal medication
• For offenders who experience psychological difficulties 
and distress in the form of intrusive and obsessive 
thoughts about sex, compulsive sexual behaviour,  
compulsive masturbation, and very frequent sexual 
arousal, and for offenders in whom sexual arousal is 
associated with negative mood states.    
• Can assist users to engage in offending behaviour 
programmes and services, or help them avoid high risk 
situations.
• Always offered within a psychologically informed 
framework
Who is it for?
• Offenders with a sexual element to their offending 
• Over 18, men and women
• Who complain of:
– sexual pre-occupation
– high levels of  sexual arousal
– deviant sexual fantasy which is subjectively difficult to control
– sex as way of coping with low mood or anxiety
• Completely voluntary
• Offered at an appropriate time in sentence
Psychological difficulties and distress including: Intrusive and obsessive 
thoughts about sex, deviant arousal or problem sexual behaviour 
associated with low mood or anxiety, sexual arousal or behaviour that is 
subjectively difficult to manage, high sex drive.   Psychometrically 
determined sexual preoccupation.
Low Symptom Medium symptom High Symptom
Risk of harmful 
sexual
offending
as measured 
by a suitable risk 
assessment 
(RM2000,  OSP, 
or SARN)
Low risk of 
harm
Not indicated
Not indicated Indicated
Medium risk of 
harm Not indicated Consider Indicated
High risk of 
harm Consider Consider Indicated
Some basic principles of sexual arousal
• sex drive is biological
• no one chooses their sexual arousal profile
• difference between arousal and control of arousal
• attitudes & beliefs, emotional state, self-management,
influence sexual behaviour
• the most important male sex organ is:
Sexual
thoughts, drive
Attitudes, beliefsEmotional state
Behavioural
controls
M dicat on
Medication for sex offenders
medical treatment
v
social control
- consent
- confidentiality
• some work with you
• some are ambivalent
• some don’t want to know
The Neurobiology of 
Sexual Arousal
Hypothalamus
Pituitary
Testes
Gonadotropin hormone
releasing hormone
(GnRH)
Lutenising hormone
(LH)
Follicle stimulating hormone
(FSH)
Testosterone
~5% produced by
adrenal glands
THE REST OF THE BRAIN
T neg. feedback
limbic system
5-HT                dopamine
Testosterone reduces 
sexual interest more than sexual function
Anti-androgens: depo-Provera (Oregon) 
(Maletzky, Tolan & McFarland, 2006))
Provera No Provera Not recom.
n=79 n=55 n=141
sex recidivism 0 10 (18%) 21 (15%)
sex breech 1 12 (22%) 6  (4%)
in prison 0 11 (20%) 19 (13%)
‘doing well’ 70 (89%) 24 (44%) 89 (63%)
GNRH agonists: Triptorelin (Rosler & 
Witztum, 1998)
n = 30
“hypersexual”: masturbate 32/week
fantasise     48/week
behaviour   5/month
failed on other Rx
dropout = 6 (20%)
{3 from side effects}
Triptorelin (Rosler & Witztum, 1998)
RESULTS
follow-up to 31/2 years
masturbation       = 0-1 per week
deviant fantasies = 0
behaviours          = 0
reoffences = 0 {except for 2 side effect
drop outs}
testosterone reduction: 95%
LH reduction: 90%
bone mineral density:  40-50%
Schober (www.clinicaltrials.gov)
N=5
CBT for 2 years; luprolide year one, saline year two
Results
- decrease but no difference in ppg, Abel Screen
- all reported decreased in fantasies, urges and masturbation
- polygraph: at baseline and placebo, deceptive
anti-androgens side effects
• menopausal symptoms
(hot flushes, depression, weight gain, cvs)
• gynaecomastia
• osteoporosis
• carbohydrate metabolism, other endocrine
GnRH side effect kinder?
SSRIs: the studies
decrease in strength and frequency of fantasies
decrease in sexual urges
decrease in masturbation
decrease in behaviours
delay in ejaculation
SSRIs: Mode of Action?
• OCD
• impulsivity
• mood enhancement
• all of the above
• reduction in sex drive
• reduction in orgasmic enjoyment
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Background
• Interventions with sex offenders in UK prisons are 
primarily psychological in nature, adopting a CBT 
approach.
• High levels of sexual preoccupation and hypersexuality in 
high risk offenders appears to interfere with engagement 
on psychological treatments, potentially resulting in poor 
outcome on programmes.
• Evidence suggests the potential for use of medical 
treatment in aiding the management and treatment of risk 
factors such as sexual preoccupation / obsession.
• This is important since sexual preoccupation (both in the 
offence chain and generally) is the most  frequently 
occurring ‘strongly present’ risk factor in sex offenders.
Proportion of prisoners scoring ‘strongly present’ on most 
frequently occurring SARN risk factors
Context
• HMP Whatton holds approximately 840 adult males convicted of 
a sexual offence (or where there is a sexual element to their 
offence). It is one of the largest sex offender prisons in Europe. 
Forty-two percent have a sentence of more than four years.
• 46% are serving an indeterminate sentence including life 
sentence.
• RM 2000 scores 
o 37 % high / very high
o 40 % medium
HMP Whatton started offering MMSA in November 2009
• Drugs used 
o Fluoxetine, Paroxetine (SSRIs)
o Cyproterone acetate (CPA, anti androgen)
o Triptorelin (GnRH agonist)
• Treatment Pathway
Results from the Evaluation
• Clinical measures:
– Captured at regular meetings between participants and Dr Kaul (prescribing 
psychiatrist)
– Data collated during private therapeutic session
– Used clinically to discuss and tailor medication
– Data then transferred to research team where it is collated and organised
systematically
• Psychometric measures:
Dynamic measures (baseline pre-meds, then approximately every 3 months)
– Sexual Compulsivity Scale (SCS)
• 10 items; 1-4; used means i.e. between 1-4; ‘My desires to have sex have disrupted my 
daily life’
– Hospital Anxiety and Depression Scale (HADS)
• Scoring is 0-21 on each sub-scale; caseness 8/21
– Severity Indices of Personality Problems (SIPP 118)
Time spent thinking about sex 
High 
Paired t test shows significant drop 
between T0 and T3 for SSRI 
(t=8.53, 41, p=0.001) 
Clinical measures: number of days 
masturbating per week
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Clinical measures: number of days masturbating 
per week - all meds combined
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Main effect of Time F(3,147) = 31.82 p = 0.001; ηρ
2 .394
Baseline - T1, P = 0.001
T1-T3 ns
T3-T6 ns
Results from sexual compulsivity scale
Figure 1: Mean Sexual Compulsivity Scores for participants taking medication to 
reduce sexual preoccupation: pre-medication (T0), three months post-
medication (T3) and six months post-medication (T6).
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Personality and sexual offending 
• Prevalence rate for PD in sexual offending populations varies between 
94% (McElroy et al.,1999) and 33% (Fazel, Hope, O’Donnell & Jacoby, 
2002) compared to general population of between 2-11%.
• Cluster B (dramatic) PDs appear to be more prevalent in rapists, and 
cluster C (anxious) PDs are thought to be more prevalent in child 
molesters.
• Research has found that problematic personality traits are a key 
predictor of sexual recidivism, especially when paired with a deviant 
sexual interest (Hanson & Morton-Bourgon, 2005).
• However very little empirical investigation has explored the link 
between SP and personality. 
• The theoretical explanations of both SP and problematic personality 
share some similarities, particularly in relation to self- management 
factors. For example urge management/impulse control are considered 
to be problematic mechanisms in both PD and SP.
Dimensional concept of PD
• The view that personality was not susceptible to change had serious 
implications for treatment attempts (Andrea et al., 2007). 
• Research increasingly suggests that personality is more changeable or 
adaptive than previously believed (see Specht, Egloff & Schmukle, 
2011).
• Adaptive personality functioning is considered to be a person’s ability 
to be able to adapt to the situation or environment in relation to their 
personality traits (Andrea et al., 2007). For example, learning to have 
control over one’s emotions and impulses. 
• Maladaptive personality functioning refers to an individual’s inability to 
adapt their personality to the needs of the environment or situation 
(Andrea et al., 2007). 
Analysing PD in the current sample - Procedure
• Researchers carried out the SIPP-118 questionnaire 
with individuals. 
• Standardised prompts were developed for those with 
lower understanding of the questions, and response 
options were presented verbally and in a visual 
format.  
• The first administration of the SIPP-118 occurred 
before medication was commenced (referred to as 
‘baseline’) and this process was repeated 
approximately every three months after medication.
Percentage of clinically significant change of participants between baseline 
and six months on SIPP-118 scales
Scale Baseline % of participants with
maladaptive functioning
N (69)
Six months % of participants
with maladaptive functioning
N (41)
% reliable
change
Emotional
regulation 68.12 29.27 38.85
Effortful control
76.81 46.34 30.47
Frustration
tolerance 62.32 26.83 35.49
Responsible
industry 57.97 43.90 14.07
Aggression
regulation 47.83 34.15 13.68
Intimacy 47.83 24.39 23.44
Enduring
relationships 66.67 46.34 20.33
Self-respect 57.97 21.95 36.02
Results – SIPP - 118
• Prior to starting medication the research sample more closely 
resembled the clinical population (admissions to mental health 
institutes) than the general population on the SIPP-118. 
• The facets most problematic were effortful control, self-reflexive 
functioning, frustration tolerance, emotional regulation and stable self 
image.
• Provides support for the hypothesis that the adaptive personality 
functioning in the domains of  self-control and relationships, of 
sexually preoccupied males convicted of a sexual offence was more 
problematic  than the general population norms. 
• Both statistical and clinically significant change was observed in 
adaptive personality functioning on all scales by six months post 
medication. The percentage of reliable change of adaptive 
personality functioning was between 13.6% and 38.8%, moving 
functioning from the maladaptive range to the clinically ‘normal’ 
range (general population norms). 
• The majority of participants had moved into the healthy range of 
personality functioning within six months of taking medication.
• The results add some tentative support for the second hypothesis 
that medication to treat SP improves adaptive functioning on 
personality areas linked to self-control and relationships.
Results – continued
How do OM and OSs feel about the use of MMSA?
• Qualitative study
• Participants were 12 OMs/OSs
• Thematic analysis of semi-structured interview data
• Analysis: Two superordinate themes
The dangers of not knowing
Who is taking it?
Lack of trust
What happens next?
Treatment Awareness
Scepticism to optimism
Out of the loop
Mandatory vs voluntary
Qualitative research with prisoners
 Qualitative research interviews with prisoners
 Preliminary findings:
 Reductions in the number and intensity of sexual thoughts and 
fantasies
 Improvements in mood and concentration
 Increased control over impulsive and/or compulsive behaviour –
anger, OCD   
 Reduction in / loss of sexual arousal – implications?
 Side effects and compliance issues
How do I access it for my prisoner?
• Community on a case by case basis, through the 
Offender Personality disorder service in your LDU
NOTE prisoner does not have to be screened into the 
pathway to access the medication!
• Frankland - HSE
• Isle of Wight – Cat B
• Hull – Sex offender PIPE
• Whatton – Cat C
• Usk – Cat C
• North Sea Camp – Cat D
• Leyhill – Cat D
Contacts – prison services
• Frankland Kimberley.Gibson@hmps.gsi.gov.uk
• IOW Jacob.Seaward@hmps.gsi.gov.uk
• Whatton philippa.lister@hmps.gsi.gov.uk
• Hull Jolene.Jones@hmps.gsi.gov.uk
• Leyhill Martine.Ratcliffe@hmps.gsi.gov.uk
• North Sea Camp jen.munns@hmps.gsi.gov.uk
• Usk - cerys.miles@hmps.gsi.gov.uk
• HMPS Lead Martin.Fisher@hmps.gsi.gov.uk
• SOTP Lead Jamie.Walton@noms.gsi.gov.uk
Contacts – OPD commissioners
Region/Function NOMS and NHS Leads
North of England Neil Piggin, neil.piggin@noms.gsi.gov.uk
Mick Burns, mick.burns@nhs.net
Midlands and East of England Rachel Wilson, rachel.wilson@noms.gsi.gov.uk
Peter Howe, peter.howe1@nhs.net
London Laura d’Cruz, Laura.dCruz@noms.gsi.gov.uk
Mary O’Donnell, maryo'donnell@nhs.net
South of England Nick Joseph, nick.joseph@noms.gsi.gov.uk
Zoe Thornton, zoe.thornton@nhs.gsi.gov.uk
Wales Nick.Joseph, nick.joseph@noms.gsi.gov.uk
Women Offenders Laura d’Cruz, laura.dCruz@noms.gsi.gov.uk
Therapeutic Environments
Therapeutic Communities
Kirk Turner, kirk.turner@noms.gsi.gov.uk
Jennie Slater, jennie.slater@noms.gsi.gov.uk
Research and Evaluation Kathryn Harney, Kathryn.Harney@gmw.nhs.uk
Heads of Offender PD team
Ian Goode;  Joint Head of Offender Personality Disorder Co-
commissioning
Commissioning Group, 
Directorate of Commissioning
National Offender Management Service
3rd Floor, Clive House
70 Petty France 
London 
SW1H 9HD
Ian.Goode@noms.gsi.gov.uk or PD@noms.gsi.gov.uk
Sarah Skett; Joint Head of Offender Personality Disorder Co-
commissioning
NHS England Specialised Commissioning
sarah.skett@nhs.net or PD@noms.gsi.gov.uk
Questions?
